Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Landi

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Cancer Research|November 30, 2017
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast CancerTiara T Byrd, Kristen Fousek, Antonella Pignata, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 12, 2022
Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyAmar Gajjar, Anita Mahajan, Mohamed Abdelbaki, et al.
Nature Cancer|June 12, 2025
A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trialEric M Thompson, David M Ashley, Katayoun Ayasoufi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyAmar Gajjar, Anita Mahajan, Tejus Bale, et al.
JAMA Oncology|April 21, 2017
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation TrialNabil Ahmed, Vita Brawley, Meenakshi Hegde, et al.
Cancer Research Communications|February 20, 2025
A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell FunctionDaniel Landi, Shoba A Navai, Rebecca M Brock, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Cancer Research|November 30, 2017
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast CancerTiara T Byrd, Kristen Fousek, Antonella Pignata, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 12, 2022
Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyAmar Gajjar, Anita Mahajan, Mohamed Abdelbaki, et al.
Nature Cancer|June 12, 2025
A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trialEric M Thompson, David M Ashley, Katayoun Ayasoufi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyAmar Gajjar, Anita Mahajan, Tejus Bale, et al.
JAMA Oncology|April 21, 2017
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation TrialNabil Ahmed, Vita Brawley, Meenakshi Hegde, et al.
Cancer Research Communications|February 20, 2025
A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell FunctionDaniel Landi, Shoba A Navai, Rebecca M Brock, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Pageof 3